Consultation: NENC Clinical Pathway for the Prescribing and Monitoring of GnRH Antagonists for Endometriosis
Following the September 2026 NENC Clinical Guidelines & Pathways Group we now seek comments from across the NENC ICB on this new draft NENC Clinical Pathway for the Prescribing and Monitoring of GnRH Antagonists for Endometriosis.
This guideline has been developed by the NENC ICB to establish a consistent regional standard for the initiation, transfer of prescribing and monitoring of Linzagolix and Ryeqo® when used for endometriosis.
Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the Clinical Guidelines & Pathways Group/NTAG, and used to inform the final version that is presented for approval in the NENC.
All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.
All comments received will shared unedited with the authors/working group who are developing the document to support the production of a final draft for approval.
Please note
- The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to nuth.nyrdtc.rxsupp@nhs.net
- This consultation will run for four weeks and closes on Friday 9th October at 5pm.
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
|
New 11/09/2026 |
NENC Clinical Pathway for the Prescribing and Monitoring of GnRH Antagonists for Endometriosis |